These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30635159)

  • 21. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.
    Holley RJ; Ellison SM; Fil D; O'Leary C; McDermott J; Senthivel N; Langford-Smith AWW; Wilkinson FL; D'Souza Z; Parker H; Liao A; Rowlston S; Gleitz HFE; Kan SH; Dickson PI; Bigger BW
    Brain; 2018 Jan; 141(1):99-116. PubMed ID: 29186350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
    King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
    Yogalingam G; Hopwood JJ
    Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
    King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.
    Li HH; Yu WH; Rozengurt N; Zhao HZ; Lyons KM; Anagnostaras S; Fanselow MS; Suzuki K; Vanier MT; Neufeld EF
    Proc Natl Acad Sci U S A; 1999 Dec; 96(25):14505-10. PubMed ID: 10588735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study.
    Seo JH; Kosuga M; Hamazaki T; Shintaku H; Okuyama T
    Mol Genet Metab; 2023 Dec; 140(4):107709. PubMed ID: 37922836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Femoral Structure and Biomechanical Characteristics in Sanfilippo Syndrome Type-B Mice.
    Ashby FJ; Castillo EJ; Ludwig Y; Andraka NK; Chen C; Jamieson JC; Kabbej N; Sommerville JD; Aguirre JI; Heldermon CD
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
    Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H
    Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.
    Aoyagi-Scharber M; Crippen-Harmon D; Lawrence R; Vincelette J; Yogalingam G; Prill H; Yip BK; Baridon B; Vitelli C; Lee A; Gorostiza O; Adintori EG; Minto WC; Van Vleet JL; Yates B; Rigney S; Christianson TM; Tiger PMN; Lo MJ; Holtzinger J; Fitzpatrick PA; LeBowitz JH; Bullens S; Crawford BE; Bunting S
    Mol Ther Methods Clin Dev; 2017 Sep; 6():43-53. PubMed ID: 28664165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB).
    Beesley CE; Jackson M; Young EP; Vellodi A; Winchester BG
    J Inherit Metab Dis; 2005; 28(5):759-67. PubMed ID: 16151907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Untypically mild phenotype of a patient suffering from Sanfilippo syndrome B with the c.638C>T/c.889C>T (p.Pro213Leu/p.Arg297Ter) mutations in the NAGLU gene.
    Pierzynowska K; Mański A; Limanówka M; Wierzba J; Gaffke L; Anikiej P; Węgrzyn G
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1356. PubMed ID: 32578945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
    Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central nervous system pathology in preclinical MPS IIIB dogs reveals progressive changes in clinically relevant brain regions.
    Egeland MT; Tarczyluk-Wells MM; Asmar MM; Adintori EG; Lawrence R; Snella EM; Jens JK; Crawford BE; Wait JCM; McCullagh E; Pinkstaff J; Cooper JD; Ellinwood NM
    Sci Rep; 2020 Nov; 10(1):20365. PubMed ID: 33230178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defective heparan sulfate metabolism in the Sanfilippo syndrome and assay of this defect in the assessment of the mucopolysaccharidoses patient.
    Gordon BA; Feleki V; Budreau CH; Tyler L
    Clin Biochem; 1975 Jun; 8(3):184-93. PubMed ID: 238759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B.
    Prill H; Luu A; Yip B; Holtzinger J; Lo MJ; Christianson TM; Yogalingam G; Aoyagi-Scharber M; LeBowitz JH; Crawford BE; Lawrence R
    Mol Ther Methods Clin Dev; 2019 Sep; 14():56-63. PubMed ID: 31309128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
    Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
    Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous administration of human umbilical cord blood cells in an animal model of MPS III B.
    Garbuzova-Davis S; Klasko SK; Sanberg PR
    J Comp Neurol; 2009 Jul; 515(1):93-101. PubMed ID: 19399896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.